Compare Stocks: XCUR, GOSS, QNCX, and SGMO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$11.52 +5.3%	$12.98	$9.10 ▼ $309.60	$66.85M	2	233,765 shs	516,355 shs
QNCX Quince Therapeutics	$29.00 -6.5%	$28.85	$15.10 ▼ $909.98	$31.53M	1.31	18,949 shs	40,769 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A
XCUR Exicure	$1.21 -1.2%	$1.40	$1.05 ▼ $9.48	$7.99M	3.63	31,306 shs	2,571 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	0.00%	+1.96%	-19.61%	-16.62%	-94.94%
QNCX Quince Therapeutics	0.00%	+5.16%	-8.15%	+68.37%	-90.37%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-88.86%
XCUR Exicure	0.00%	-1.63%	-6.20%	-45.00%	-68.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$11.52 +5.3%	$12.98	$9.10 ▼ $309.60	$66.85M	2	233,765 shs	516,355 shs
QNCX Quince Therapeutics	$29.00 -6.5%	$28.85	$15.10 ▼ $909.98	$31.53M	1.31	18,949 shs	40,769 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A
XCUR Exicure	$1.21 -1.2%	$1.40	$1.05 ▼ $9.48	$7.99M	3.63	31,306 shs	2,571 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	0.00%	+1.96%	-19.61%	-16.62%	-94.94%
QNCX Quince Therapeutics	0.00%	+5.16%	-8.15%	+68.37%	-90.37%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-88.86%
XCUR Exicure	0.00%	-1.63%	-6.20%	-45.00%	-68.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOSS Gossamer Bio	2.22	Hold	$256.00	2,122.22% Upside
QNCX Quince Therapeutics	2.62	Moderate Buy	$206.71	612.81% Upside
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, GOSS, QNCX, and SGMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/22/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
9/22/2026	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$77.00
9/8/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$68.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOSS Gossamer Bio	$48.47M	1.45	N/A	N/A	($42.43) per share	-0.27
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85
XCUR Exicure	$500K	15.79	N/A	N/A	$0.62 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A
XCUR Exicure	-$4.95M	-$1.32	N/A	N/A	N/A	N/A	-237.91%	-61.98%	11/12/2026 (Estimated)

Latest XCUR, GOSS, QNCX, and SGMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/14/2026	Q2 2026	XCUR Exicure	-$18.60	-$0.18	+$18.42	-$0.18	$1.64 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOSS Gossamer Bio	N/A	0.53	0.53
QNCX Quince Therapeutics	N/A	14.52	14.52
SGMO Sangamo Therapeutics	N/A	0.84	0.84
XCUR Exicure	N/A	0.56	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOSS Gossamer Bio	81.23%
QNCX Quince Therapeutics	30.75%
SGMO Sangamo Therapeutics	56.92%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
GOSS Gossamer Bio	4.15%
QNCX Quince Therapeutics	5.60%
SGMO Sangamo Therapeutics	4.10%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOSS Gossamer Bio	162	6.11 million	5.86 million	Optionable
QNCX Quince Therapeutics	38	1.02 million	960,000	Optionable
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable
XCUR Exicure	50	6.55 million	3.09 million	Not Optionable

XCUR, GOSS, QNCX, and SGMO Headlines

Recent News About These Companies

Contrasting ProQR Therapeutics (NASDAQ:PRQR) & Exicure (NASDAQ:XCUR)

September 27 at 8:58 AM | americanbankingnews.com

Exicure stock falls 2.24 percent with Nasdaq deadline ahead

September 25 at 2:44 PM | ad-hoc-news.deA

Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26

September 16, 2026 | rttnews.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

September 16, 2026 | finance.yahoo.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

September 16, 2026 | globenewswire.com

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, GOSS, QNCX, and SGMO Company Descriptions

Gossamer Bio NASDAQ:GOSS

$11.52 +0.58 (+5.30%)

Closing price 04:00 PM Eastern

Extended Trading

$11.45 -0.07 (-0.62%)

As of 07:56 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Quince Therapeutics NASDAQ:QNCX

$29.00 -2.00 (-6.45%)

Closing price 04:00 PM Eastern

Extended Trading

$29.04 +0.04 (+0.14%)

As of 07:30 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 09/25/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Exicure NASDAQ:XCUR

$1.20 -0.02 (-1.23%)

Closing price 03:57 PM Eastern

Extended Trading

$1.21 +0.01 (+0.58%)

As of 07:30 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, GOSS, QNCX, and SGMO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, GOSS, QNCX, and SGMO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, GOSS, QNCX, and SGMO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, GOSS, QNCX, and SGMO Company Descriptions

Gossamer Bio NASDAQ:GOSS

Quince Therapeutics NASDAQ:QNCX

Sangamo Therapeutics NASDAQ:SGMO

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, GOSS, QNCX, and SGMO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, GOSS, QNCX, and SGMO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, GOSS, QNCX, and SGMO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, GOSS, QNCX, and SGMO Company Descriptions

Gossamer Bio NASDAQ:GOSS

Quince Therapeutics NASDAQ:QNCX

Sangamo Therapeutics NASDAQ:SGMO

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools